Oncology Learning NetworkOsimertinib Plus Datopotamab Deruxtecan in EGFR-Mutated Advanced NSCLC

⚠️ Small Study / Early Comparative Evidence

The ORCHARD platform substudy evaluated osimertinib plus datopotamab deruxtecan in EGFR-mutated advanced NSCLC after first-line osimertinib progression. The 6 mg/kg cohort showed median duration of response of 20.5 months versus 6.3 months at 4 mg/kg, with corresponding increases in toxicity.

Clinical Considerations

• Overall response rates were 43% (4 mg/kg) and 36% (6 mg/kg), with median overall survival reaching 26.2 months in the higher-dose cohort
• Grade ≥3 adverse events occurred in 76% of the 6 mg/kg cohort versus 49% at 4 mg/kg, with dose reductions in 59% versus 23%
• Adjudicated interstitial lung disease reached 15% at 6 mg/kg compared with 3% at 4 mg/kg, requiring active monitoring
• Continuing osimertinib alongside the antibody-drug conjugate offers potential CNS penetration and nonoverlapping resistance mechanisms

Practice Applications

• Recognize the 6 mg/kg dose is moving into TROPION-Lung14 and TROPION-Lung15 randomized trials
• Monitor for interstitial lung disease and pneumonitis given the dose-dependent incidence
• Integrate prophylactic dexamethasone mouthwash for stomatitis when this combination enters broader use
• Interpret results as hypothesis-generating pending randomized trial readouts in first- and second-line settings

More in Antibody-Drug Conjugates